Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (EP1711618) PROCEDE DE DETECTION DE MARQUEURS ASSOCIES A LA MALADIE OU LA PHASE DE L'ENDOMETRE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique
Claims

1. A method for screening a subject for endometrial cancer comprising (a) detecting in a sample from the subject an amount of an endometrial cancer marker or polynucleotide encoding the endometrial cancer marker; and (b) comparing the amount of endometrial cancer marker or polynucleotide detected to a standard, where detection of a level of endometrial cancer marker or polynucleotide different than that of a standard is indicative of endometrial cancer, and wherein the endometrial cancer marker is chaperonin 10 of SEQ ID NO. 1, a sequence with 80% sequence identity to SEQ ID NO. 1 having the immunogenic activity of SEQ ID NO. 1 or a fragment of SEQ ID NO. 1 having the ability to form antibodies specific for SEQ ID NO. 1.
  2. A method of claim 1 wherein the level of endometrial cancer marker is significantly higher compared to the standard and is indicative of endometrial cancer.
  3. A method of claim 1 wherein the level of endometrial cancer marker is significantly lower compared to the standard and is indicative of endometrial cancer.
  4. A method as claimed in claim 1, 2 or 3 wherein the sample is obtained from tissues, extracts, cell cultures, cell lysates, lavage fluid, or physiological fluids.
  5. A method as claimed in claim 4 wherein the sample is obtained from a tumor tissue.
  6. A method as claimed in claim 1 wherein the polynucleotide detected is mRNA.
  7. A method as claimed in claim 6 wherein the mRNA is detected using an amplification reaction.
  8. A method as claimed in claim 7 wherein the amplification reaction is a polymerase chain reaction employing oligonucleotide primers that hybridize to the polynucleotide, or complements of such polynucleotide.
  9. A method as claimed in claim 6 wherein the mRNA is detected using a hybridization technique employing oligonucleotide probes that hybridize to the polynucleotide or complements of such polynucleotide.
  10. A method as claimed in claim 9 wherein the mRNA is detected by (a) isolating mRNA from the sample and combining the mRNA with reagents to convert it to cDNA; (b) treating the converted cDNA with amplification reaction reagents and primers that hybridize to the polynucleotide, to produce amplification products; (c) analyzing the amplification products to detect an amount of mRNA encoding the endometrial cancer marker; and (d) comparing the amount of mRNA to an amount detected for normal tissue derived using similar primers.
  11. A method as claimed in any one of claims 1 to 5 wherein the endometrial cancer marker is detected by contacting the sample with an antibody that specifically binds to the endometrial cancer marker.
  12. A method as claimed in claim 11 wherein the antibody is used in a radioimmunoassay, enzyme immunoassay, microarray, competitive immunoassay, non-competitive immunoassay, or immunofluorescence, immunoprecipiation, latex agglutination, hemagglutination, histochemical or bioluminescence assay.
  13. A method as claimed in any preceding claim wherein the standard comprises levels of the endometrial cancer marker or polynucleotide for control samples from healthy subjects.
  14. A method as claimed in any preceding claim wherein the standard comprises levels of the endometrial cancer marker or polynucleotide for another sample or an earlier sample of the subject.